Effect of a Concurrent Training Program with and Without Metformin Treatment on Metabolic Markers and Cardiorespiratory Fitness in Individuals with Insulin Resistance: A Retrospective Analysis

Azocar-Gallardo J.; Ojeda-Aravena A.; Martin E.B.S.; Herrera-Valenzuela T.; Tuesta, M.; González-Rojas, L; Calvo-Rico, B; Garcia-Garcia J.M.

Keywords: insulin sensitivity, retrospective studies, cardiorespiratory fitness, Physical and Rehabilitation Medicine, pharmacologic treatment

Abstract

Background: Type 2 diabetes mellitus is a metabolic disorder characterized by insulin resistance (IR), which is prevalent worldwide and has significant adverse health effects. Metformin is commonly prescribed as a pharmacological treatment. Physical exercise is also recognized as an effective regulator of glycemia, independent of metformin. However, the effects of inter-day concurrent training (CT)-which includes both endurance and resistance exercises-combined with metformin treatment on metabolic markers and cardiorespiratory fitness in individuals with IR remain controversial. Objective: This study aimed to analyze the effects of a 12-week inter-day CT program on metabolic markers and cardiorespiratory fitness in overweight/obese individuals with IR, both with and without metformin treatment. Additionally, inter-individual responses to CT were examined. Materials and Methods: Data from the 2022-2023 Obesity Center database were retrospectively analyzed. According to the eligibility criteria, 20 overweight/obese individuals diagnosed with IR participated in a 12-week CT program (three weekly sessions: two endurance and one resistance exercise session). Participants were divided into three groups: the exercise group (E-G: n = 7, 32.86 +/- 8.32 years, 85.2 +/- 19.67 kg), the exercise-metformin group (E-MG: n = 6, 34.83 +/- 12.91 years, 88.13 +/- 12.66 kg), and the metformin-only control group (M-G: n = 7, 34.43 +/- 13.96 years, 94.23 +/- 13.93 kg). The M-G did not perform physical exercise during the 12 weeks but continued pharmacological treatment. Body composition, metabolic markers, and cardiorespiratory fitness were assessed before and after the 12-week CT program. Results: A group-by-time interaction was observed for fasting insulin (F-2,F-17 = 34.059, p < 0.001, eta(2)p = 0.88), the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (F-2,F-17 = 35.597, p < 0.001, eta(2)p = 0.80), and maximal fat oxidation (MFO) (F-2,F-17 = 4.541, p = 0.026, eta(2)p = 0.348) following the CT program. The maximal oxygen uptake (VO2(max)) showed significant improvements in the E-G (F = 4.888, p = 0.041, triangle+13.3%). Additionally, the percentage of fat mass (%FM) and body mass (BM) were significantly reduced across all groups (F = 125.244, p < 0.001 and F = 91.130, p < 0.001, respectively). The BM decreased by triangle-9.43% in the E-G (five responders, Rs), triangle+9.21% in the EM-G (5 Rs), and triangle+5.15% in the M-G (3 Rs). The %FM was reduced in the E-G by triangle-22.52% (seven Rs). Fasting insulin and the HOMA-IR significantly improved in both the E-G and EM-G, with fasting insulin showing a triangle-82.1% reduction in the E-G (five Rs) and a triangle-85% reduction in the EM-G (six Rs). Similarly, the HOMA-IR improved by triangle+82.6% in the E-G (three Rs) and by triangle+84.6% in the EM-G (six Rs). Conclusions: The 12-week inter-day concurrent training program, whether combined with metformin or not, was similarly effective in improving metabolic markers in patients with insulin resistance as metformin treatment alone. Both exercise groups demonstrated a significant reduction in insulin sensitivity and an increase in maximal fat oxidation. Meanwhile, exclusive pharmacological treatment with metformin markedly decreased cardiorespiratory fitness, and consequently, fat oxidation.

Más información

Título según WOS: Effect of a Concurrent Training Program with and Without Metformin Treatment on Metabolic Markers and Cardiorespiratory Fitness in Individuals with Insulin Resistance: A Retrospective Analysis
Volumen: 14
Número: 11
Fecha de publicación: 2024
Idioma: English
DOI:

10.3390/biom14111470

Notas: ISI